Goldman Sachs’s Gain Therapeutics GANX Stock Holding History

Goldman Sachs’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-32,494	Closed	-$105K	–	6682
2025 Q4	$105K	Buy	+32,494	New	+$86.7K	﹤0.01%	6180

Other funds holding GANX

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

PCM

Potomac Capital Management New York $115M AUM

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Goldman Sachs's GANX Position: Q1 2026 in Review

Goldman Sachs sold out of Gain Therapeutics (GANX) in Q1 2026, closing a stake of 32,494 shares — an estimated $105K sold.

Goldman Sachs first reported a position in GANX in Q4 2025 and held it in 1 quarter. The position peaked at $105K in Q4 2025. 42 funds tracked by Wall St. Rank hold GANX as of Q1 2026.

Goldman Sachs reported no remaining Gain Therapeutics position as of Q1 2026 after selling out during the quarter.
Goldman Sachs sold 32,494 Gain Therapeutics shares in Q1 2026, an estimated $105K.
Goldman Sachs first reported a position in Gain Therapeutics in Q4 2025 and held it in 1 quarter.
Goldman Sachs's Gain Therapeutics position peaked at $105K in Q4 2025.
42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.